- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02082990
Primary Care-based Facilitated Access to a Web Based Brief Intervention to Reduce Alcohol Consumption (EFAR-Spain)
A Randomised Controlled Non-inferiority Trial of Primary Care-based Facilitated Access to a Web Based Brief Intervention to Reduce Alcohol Consumption (EFAR-Spain)
Brief Interventions (BIs) for risky drinkers are an effective tool in primary care. Lack of time in daily practice has been identified as a barrier for the wide implementation of BI. There is growing evidence that e-health tools such as web based BIs can be an efficient alternative to standard face-to-face BIs and save time to general practitioners (GP).
The main aim of this study is to test non-inferiority of a web based BI for risky drinkers against a traditional face to face BI delivered by a general practitioner. We have designed a randomised controlled non-inferiority trial comparing both interventions, to be performed in primary care health centres in Catalonia, Spain.
Adults attending in primary care centres and willing to participate, will be invited to fill the short Alcohol Use Disorders Identification Test (AUDIT-C) in a specific website. Those screening positive and who accept to share the baseline data with their GP will be invited to an online assessment of their drinking and randomized to a standard BI with their GP or to the online BI.
Follow-up assessment will be conducted online at months 3 and 12, using the full Alcohol Use Disorder Identification Test (AUDIT) and the quality of life questionnaire (D5-EQD5). The main outcome will be the proportion of risky drinkers according to the AUDIT. Assuming a 30% reduction in the proportion of risky drinkers in the control group (classroom), allowing for an overall attrition of 10% of patients in the trial and non-inferiority assessed against a specified margin of 10%, it is estimated that 500 patients would be required in each group to give the test a 90% power (1-β) to reject the null hypothesis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Trial design: A randomised non-inferiority controlled trial in primary care comparing facilitated access to a website for risky drinkers against a standard face-to-face BI. With the exception of the non-experimental intervention, all components of the study will be administered online to patients. Patients will be actively encouraged by their PHCP to access the application, which is available on the website of the programme 'Alcohol y Salud' (http:// www.alcoholysalud.cat), and will be provided with a unique registration code. The trial website is a Spanish adaptation of the English version of http://www.DownYourDrink.org.uk (DYD) developed in the UK, which includes modules for all the key trial components including screening, consent, assessment, randomisation and follow-up. It also incorporates the alcohol reduction website for the patients in the experimental group. The site has been adapted from the http://www.DownYourDrink.org.uk website developed for the DYD-RCT (randomised controlled trial).14 Details of DYD and the psychological theory that underpinned its development have been reported elsewhere. 21 Country-specific information such as recommended guidelines for alcohol intake, definitions of standard drinks and alcohol-related laws will be included. The website also incorporates a menu-driven facility to enable PHCP to customise automated messages to patients, for example, by adding photographs and pre-recorded messages. The personalised messages will appear to each patient using the log-in code provided by that practitioner.
Practitioner recruitment, training and incentives:
Recruitment will be based on the XaROH network. A 3 h seminar on new technologies, and EI and BI, introducing the trial, will be offered to all members of the XaROH, and those attending will be invited to sign up for the trial. In addition, several advertisements will be posted on the 'Beveu Menys' platform offering participation in the trial. In selecting practices, preference will be given to those with at least 5000 registered patients. Those practices that are selected as participants will be required to undergo a 1-day training programme. The training has four steps: (1) introduction to trial; (2) familiarisation with website; (3) update about EI and BI; and (4) practice in EI and BI (role-playing). Finally, participants will be encouraged to use the website and to tailor-make patient messages. Participating PHCPs will receive a financial incentive of €20 per patient recruited to the trial.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Catalonia
-
Multiple Locations, Catalonia, Spain
- Primary Care Centres of Institut Català de la Salut
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged 18 years old or over attended in primary care during the study period
- AUDIT-C 4 or above for women and 5 or above for men (in online screening)
Exclusion Criteria:
- Severe psychiatric disorders
- Serious visual impairment
- Terminal illness
- To have inadequate command of the Spanish or Catalan language
- AUDIT ≥ 18 in baseline assessment.
Excluded patients will be referred to GPs to consider other interventions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Face-to-Face Brief Intervention Group
One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
|
One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
|
Experimental: Online Brief Intervention Group
Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
|
Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of risky drinkers according to the Alcohol Use Disorder Identification Test (AUDIT)
Time Frame: At month 3 after the randomisation
|
% of patients with > 7 scoring in AUDIT (month 3)
|
At month 3 after the randomisation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of risky drinkers according to the Alcohol Use Disorder Identification Test (AUDIT)
Time Frame: at month 12 after the randomisation
|
% of patients with > 7 scoring in AUDIT (month 12)
|
at month 12 after the randomisation
|
Quality of life EQ-5D-3L questionnaire
Time Frame: at month 3 and 12 after the randomisation
|
Increasing of QoL according to EQ5D53L
|
at month 3 and 12 after the randomisation
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Implementation
Time Frame: at month 3 after the randomisation
|
Proportion of Brief Interventions carried out among the subjects who are positively screened
|
at month 3 after the randomisation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Antoni Gual, MD. PhD, Institut d'Investigacions Biomèdiques August Pi i Sunyer
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI042924
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hazardous Drinking
-
University of OsloThe Research Council of NorwayCompleted
-
University of OsloThe Research Council of NorwayCompletedHazardous Drinking | Harmful DrinkingNorway
-
University Medicine GreifswaldGerman Cancer AidCompletedHazardous DrinkingGermany
-
UConn HealthNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
University Medicine GreifswaldGerman Research FoundationCompleted
-
Brown UniversityCompletedCigarette Smoking | Hazardous DrinkingUnited States
-
Institut national de prevention et d'education...CompletedHazardous Alcohol Consumption
-
Centre for Addiction and Mental HealthCanadian Institutes of Health Research (CIHR)CompletedAlcohol Consumption | Hazardous Alcohol ConsumptionCanada
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedHazardous Drinking | Harmful DrinkingUnited States
-
Brown UniversityCompletedHIV | Hazardous DrinkingUnited States
Clinical Trials on Face-to-Face Brief Intervention
-
Andalusian School of Public HealthCompleted
-
Charite University, Berlin, GermanyDeutscher Akademischer Austausch Dienst; Swinburne University of TechnologyRecruiting
-
SangathCompletedHazardous DrinkingIndia
-
University of Sao PauloRecruiting
-
Vrije Universiteit BrusselKing's College London; University of Copenhagen; Erasmus Medical Center; University... and other collaboratorsActive, not recruitingAdvanced CancerBelgium, Netherlands, Denmark, Ireland, United Kingdom, Italy
-
Kayseri City HospitalTC Erciyes UniversityNot yet recruitingLearning | Exercise Test
-
Rhode Island HospitalEmory UniversityRecruitingHIV | Medication Adherence | TelemedicineUnited States
-
Pennington Biomedical Research CenterTHE C.B. AND IRENE PENNINGTON FOUNDATIONCompletedGlucose Intolerance | Gestational DiabetesUnited States
-
Social Insurance Institution, FinlandActive, not recruitingInformal Caregivers | Caregivers | Family CaregiversFinland
-
University Hospital, Clermont-FerrandSENS laboratory, Univ. Grenoble Alpes; INRAE, UNH, CRNH Auvergne, Clermont... and other collaboratorsCompletedObesity | Diabete Type 2France